论文部分内容阅读
近年来,基因重组干扰素-a(interferon,IFN-+)已越来越多地用于多种肿瘤,尤其是作为一种辅助治疗药物,能调节20多种细胞毒药物的作用。笔者将IFN—n与细胞毒药物联用治疗24例恶性血液病,报告如下: 1 资料与方法 1.1 一般资料 病例来源于本院1990年2月～1997年7月住院病人,诊断及疗效标准按照国内血液病诊断及疗效标准。 1.2 治疗方法 除3例毛细胞白血病(Hairy CellLeukemia,HCL)用脾切除+IFN-+治疗外,21例恶性血液病用细胞毒药物化疗与IFN-o联合应用。IFN-a用法:干扰能(Intron A,重组o-2a干扰素,美国先灵葆雅公司生产,300万U/支),罗扰素(Roferon-A,重组●-2。干扰素,上海罗氏公司生产,
In recent years, recombinant interferon (IFN-+) has been increasingly used in many kinds of tumors, especially as an adjunct therapeutic drug, which can regulate the action of more than 20 kinds of cytotoxic drugs. The author of the IFN-n and cytotoxic drugs used in the treatment of 24 cases of hematological malignancies, the report is as follows: 1 Materials and Methods 1.1 General information Cases from our hospital from February 1990 to July 1997 inpatients, diagnosis and efficacy standards in accordance with Domestic blood disease diagnosis and efficacy standards. 1.2 Treatments In addition to 3 cases of hairy cell leukemia (HCL) treated with splenectomy + IFN-+, 21 cases of hematological malignancy were treated with cytotoxic chemotherapy combined with IFN-o. IFN-a usage: interference energy (Intron A, recombinant o-2a interferon, manufactured by Schering-Plough USA, 3 million U/branch), Roferon-A (recombinant ● -2. Interferon, produced by Shanghai Roche) ,